Trial site
Clinical Research Center, H PLUS Yangji Hospital
Seoul, Gwanakgu 08779, South KoreaNot linked to an institution yet
The trials here
What the 13 trials at this site are about, from their registry records.
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd13 trials
Closed trials
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
NCT06889012· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
NCT06744439· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
NCT06744062· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
NCT06744426· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
NCT06744127· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
NCT06890299· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
NCT06890286· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions
NCT06879158· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions
NCT06879132· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
NCT06636877· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
NCT06289920· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
NCT06226727· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Completed
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"
NCT06184269· Phase 1· Boryung Pharmaceutical Co., Ltd· Source
Report an error